Agrawal Swastik, Duseja Ajay K
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Clin Exp Hepatol. 2012 Jun;2(2):122-34. doi: 10.1016/S0973-6883(12)60101-7. Epub 2012 Jul 21.
Non-alcoholic fatty liver disease (NAFLD) is an important cause of liver disease worldwide with prevalence ranging from 10% to 30% in various countries. It has become an important cause of unexplained rise in transaminases, cryptogenic cirrhosis, and cryptogenic hepatocellular carcinoma. Pathogenesis is related to obesity, insulin resistance, oxidative stress, lipotoxicity, and resultant inflammation in the liver progressing to fibrosis. Pharmacological treatment in patients with NAFLD is still evolving and the treatment of these patients rests upon lifestyle modification with diet and exercise being the cornerstones of therapy. While there are many similarities between patients with NAFLD from Asia and the West, there are certain features which make the patients with NAFLD from Asia stand apart. This review highlights the data on NAFLD from Asia comparing it with the data from the West.
非酒精性脂肪性肝病（NAFLD）是全球肝脏疾病的重要病因，在各个国家的患病率从10%到30%不等。它已成为转氨酶不明原因升高、隐源性肝硬化和隐源性肝细胞癌的重要病因。发病机制与肥胖、胰岛素抵抗、氧化应激、脂毒性以及肝脏随之发生的炎症进展为纤维化有关。NAFLD患者的药物治疗仍在不断发展，这些患者的治疗依赖于生活方式的改变，饮食和运动是治疗的基石。虽然亚洲和西方的NAFLD患者有许多相似之处，但也有一些特征使亚洲的NAFLD患者有所不同。本综述重点介绍了亚洲NAFLD的数据，并与西方的数据进行了比较。
